**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 22177**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Retrospective Study***

**Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies**

Roberson JD *et al*. Severe toxicities following 90Y microspheres

John D Roberson II, Andrew M McDonald, Craig J Baden, Chee Paul Lin, Rojymon Jacob, Omer L Burnett III

**John D Roberson II**, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-3412, United States

**Andrew M McDonald, Craig J Baden, Rojymon Jacob, Omer L Burnett III,** Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, United States

**Chee Paul Lin,** Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL 35205, United States

**Author contributions:** Roberson JD collected and analyzed the data and drafted the manuscript; Lin CP provided analytical oversight; Jacob R and Burnett OL designed and supervised the study; McDonald AM, Baden CJ, Jacob R, and Burnett OL revised the manuscript for important intellectual material support; all authors have read and approved the final version to be published.

**Supported by** the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR00165 through our institution’s Center for Clinical and Translational Science (in part). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Institutional review board** **statement:** This study was reviewed and approved by the University of Alabama at Birmingham Institutional Review Board.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to inclusion in the study.

**Conflict-of-interest** **statement:** We have no conflicts-of-interest to report.

**Data sharing statement:** Dataset is available upon request from corresponding author at jdr25@uab.edu. Consent was not obtained for data sharing but presented data are anonymized and risk of identification is low.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **John D Roberson II, BS, Medical Student**, School of Medicine, University of Alabama at Birmingham, 1720 2nd Ave. S. FOT 1203, Birmingham, AL 35294-3412, United States. jdr25@uab.edu

**Telephone:** +1-205-9345670

**Fax:** +1-205-9750784

**Received:** August 18, 2015

**Peer-review started:** August 18, 2015

**First decision:** September 29, 2015

**Revised:** November 5, 2015

**Accepted:**December 8, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To further define variables associated with increased incidences of severe toxicities following administration of yttrium-90 (90Y) microspheres.

**METHODS:** Fifty-eight patients undergoing 79 treatments were retrospectively assessed for development of clinical and laboratory toxicity incidence following 90Y administration. Severe toxicity events were defined using Common Terminology Criteria for Adverse Events version 4.03 and defined as grade ≥ 3. Univariate logistic regression analyses were used to evaluate the effect of different factors on the incidence of severe toxicity events. Multicollinearity was assessed for all factors with *P <* 0.1 using Pearson correlation matrices. All factors not excluded due to multicollinearity were included in a multivariate logistic regression model for each measurement of severe toxicity.

**RESULTS:** Severe (grade ≥ 3) toxicities occurred following 21.5% of the 79 treatments included in our analysis. The most common severe laboratory toxicities were severe alkaline phosphatase (17.7%), albumin (12.7%), and total bilirubin (10.1%) toxicities. Decreased pre-treatment albumin (OR = 26.2; *P =* 0.010) and increased pre-treatment international normalized ratio (INR) (OR = 17.7; *P =* 0.048) were associated with development of severe hepatic toxicity. Increased pre-treatment aspartate aminotransferase (AST; OR = 7.4; *P =* 0.025) and decreased pre-treatment hemoglobin (OR = 12.5; *P =* 0.025) were associated with severe albumin toxicity. Increasing pre-treatment model for end-stage liver disease (MELD) score (OR = 1.8; *P =* 0.033) was associated with severe total bilirubin toxicity. Colorectal adenocarcinoma histology was associated with severe alkaline phosphatase toxicity (OR = 5.4; *P =* 0.043).

**CONCLUSION:** Clinicians should carefully consider pre-treatment albumin, INR, AST, hemoglobin, MELD, and colorectal histology when choosing appropriate candidates for 90Y microsphere therapy.

**Key words:** Yttrium-90 microspheres; Liver metastases; Multivariate analysis; Toxicity incidence; Colorectal adenocarcinoma

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Factors associated with the development of severe (grade ≥ 3) toxicities were identified using multivariate logistic regression models using Common Terminology Criteria for Adverse Events version 4.03. We found that severe toxicities were present following 21.5% of treatments. Abnormal pre-treatment albumin and international normalized ratio (INR) were associated with development of severe hepatic toxicity. Abnormal pre-treatment aspartate aminotransferase (AST) and hemoglobin were associated with development of severe albumin toxicity. Increasing pre-treatment model for end-stage liver disease (MELD) was associated with severe total bilirubin toxicity, and colorectal adenocarcinoma with severe alkaline phosphatase toxicity. Pre-treatment albumin, INR, AST, hemoglobin, MELD, and colorectal histology should be considered when selecting appropriate candidates for 90Y microsphere therapy.

Roberson JD, McDonald AM, Baden CJ, Lin CP, Jacob R, Burnett OL. Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Yttrium-90 (90Y) microsphere brachytherapy has emerged as an important modality for the treatment of unresectable primary or secondary hepatic malignancies. Although surgery provides the greatest chance for cure, > 70% of hepatic malignancies are considered unresectable[1,2]. While normal liver parenchyma primarily receives blood from the portal vein, hepatic malignancies receive most of their blood from the hepatic artery[3]. Administration of beta-emitting 90Y microspheres into the hepatic artery exploits this dual blood supply to preferentially deliver tumoricidal radiation to hepatic malignancies while sparing normal liver parenchyma.

90Y microspheres are primarily used in the setting of salvage therapy as there is increasing evidence that they provide benefits in both time to progression and overall survival[4,5], leading to their approval for treatment of colorectal liver metastases and extensive off-label use for various other hepatic malignancies[6]. Despite these benefits, 90Y is associated with several toxicities of which clinicians must be aware. Toxicities include constitutional symptoms including nausea, vomiting, fatigue, abdominal pain, and fever, all of which comprise the transient post-embolization syndrome (PES)[7–9]. Furthermore, gastrointestinal (GI) and liver toxicities, including elevated liver function tests (LFTs), have also been reported[9–11].

The objectives of this paper are to further define factors associated with increased incidences of severe toxicities and to identify the frequency of liver, constitutional, and GI toxicities following administration of 90Y microspheres in a sequential cohort of heterogeneous patients.

**MATERIALS AND METHODS**

***Inclusion criteria and yttrium-90 procedure***

We reviewed the charts of all patients who received 90Y resin microsphere radioembolization at our institution between October 1, 2010, and September 30, 2014. All patients who received either 90Y treatment to a single lobe or sequential bilobar treatments, did not have underlying liver cirrhosis, and were seen in follow-up were included in our analysis. Patients with underlying liver cirrhosis were excluded due to its potential to complicate post-treatment liver toxicities. For the purposes of this analysis, each procedure was considered a separate event as sequential treatments were always to the other liver lobe.

All patients were initially presented at a multidisciplinary hepatobiliary conference in which radiographic imaging and labs were reviewed to determine the best course of treatment. Patients for whom 90Y treatment was recommended underwent arterial catheterization to rule out aberrant arterial anatomy and perform prophylactic coil embolization of the gastroduodenal artery and other routes of collateral flow. Patients also underwent a nuclear medicine hepatopulmonary shunt study using technetium-99m-labeled macro-albumin aggregates injected into the hepatic arteries and visualized with static anterior and posterior images. 90Y treatment was contraindicated for patients with a shunt > 20%, while shunts of 11-15% and 16%-20% required a reduction in 90Y dosage of 20% and 40%, respectively, to decrease the risk of patients developing radiation pneumonitis[12].

Approximately two weeks later, patients received 90Y microspheres whose dose was calculated using the body surface area method adjusted for lobar involvement[13–15]. Resin microspheres of 20-60 μm (SIR spheres®, SIRTeX Medical Limited, North Sydney, N.S.W. Australia) labeled with beta-emitting 90Y with a 64.2 h half-life were selectively delivered *via* the right or left hepatic artery to vessels supplying the malignancies under treatment[16].

***Data collection and endpoints***

Patients were typically seen in follow-up at 1-, 3-, and 6-months post-treatment. Baseline laboratory values were defined as pre-treatment laboratory values closest to the treatment date, often measured the day of treatment prior to administration of 90Y microspheres. For patients receiving sequential bilobar treatments, a new baseline for the second treatment was defined using pre-treatment laboratory values closest to the second treatment’s date. The 1-mo laboratory values were defined as those closest to 1-mo from the day of treatment and between 3-wk and 2-mo post-treatment, the 3-mo laboratory values were defined as those closest to 3-mo and between 2- and 4.5-mo, and the 6-mo laboratory values were defined as those closest to 6-mo and between 4.5- and 8-mo. LFT toxicities included international normalized ratio (INR), albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin and were determined using Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)[17].

Patients were recorded as having LFT toxicities if both their post-treatment CTCAE grade was 2 or higher and this grade was increased from their pre-treatment grade. Patients with baseline LFTs meeting criteria for grade 2 toxicity which did not increase to a higher grade post-treatment were not considered to have treatment toxicity. Patients were also recorded as having severe toxicities if they had post-treatment CTCAE grade ≥ 3 laboratory measurements. Incidence of other adverse outcomes was determined from clinician notes at follow-up visits. Radiographic response at 3-mo and 6-mo post-treatment was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)[18].This study was approved by our institutional review board and was compliant with Health Insurance Portability and Accountability Act. Patients signed informed consent.

***Statistical analysis***

Univariate logistic regression was performed for each variable listed in Supplementary Table 1 to test their effect on the development of severe (grade ≥ 3) liver toxicities. Within each regression model, denominators were adjusted to account for missing laboratory data. Variables associated with development of severe toxicity at a significance level of *P <* 0.10 on univariate analysis were used to generate multivariate logistic regression models for each severe toxicity. Multicollinearity was assessed using Pearson correlation matrices; for variables with *r* > 0.4, only the one with greater significance on univariate analysis was included in multivariate analysis. Overall survival was estimated using the Kaplan-Meier method. A *P* value < 0.05 was considered statistically significant in two-tailed statistical tests. All analyses were conducted using SPSS Statistics 22.0 for Windows (IBM SPSS, Chicago, IL) with statistical review by a biomedical statistician.

**RESULTS**

***Baseline Characteristics***

During 2010-2014, 76 patients underwent 104 90Y microsphere treatments. All 104 treatments were considered for inclusion in our analysis while 58 patients undergoing 79 treatments ultimately met our inclusion criteria. One patient underwent three lobar treatments with the initial sequential treatments occurring in 2011 and the third treatment in 2013. This third treatment was excluded due to the inability to rule out the effect of previous treatments on the development of any subsequent toxicities. Ten treatments (9.6%) were excluded due to underlying liver cirrhosis, and 14 treatments (13.5%) were excluded due to lack of follow-up. Mean time to initial follow-up for all treatments was 45 d (± 31; range, 4-165 d), and mean total follow-up was 274 d (± 332; range, 14-1427 d).

Baseline characteristics for each patient and treatment are presented in Table 1. Thirty-two patients who underwent 46 treatments had extrahepatic disease, while 12 treatments occurred in patients with unilobar disease. Patients typically returned home the day after treatment (*n* = 75; 94.9%). In three cases, discharge was delayed by 1-2 d for pain, nausea and vomiting, or port infection.

***Toxicity analysis***

Table 2 presents the incidence of all toxicities while Table 3 presents the incidence of severe toxicities. Treatment type was not associated with a difference in either clinical or laboratory toxicity (see Supplementary Table 2).

Univariate and multivariate binary logistic regression models were generated for the presence of any severe toxicity, severe albumin toxicity, severe ALP toxicity, and severe total bilirubin toxicity. Results of the multivariate analyses are included in Table 4 (see Supplementary Table 1 for univariate analyses). Multivariate analyses found several associations: decreased pre-treatment albumin (OR = 26.2; *P =* 0.010) and increased pre-treatment INR (OR = 17.7; *P =* 0.048) with severe hepatic toxicity, increased pre-treatment AST (OR = 7.4; *P =* 0.025) and decreased pre-treatment hemoglobin (OR = 12.5; *P =* 0.025) with severe albumin toxicity, increasing model for end-stage liver disease (MELD) score (OR = 1.8; *P =* 0.033) with severe total bilirubin toxicity, and colorectal adenocarcinoma histology with severe alkaline phosphatase toxicity (OR = 5.4; *P =* 0.043).

***Radiographic response and overall survival***

Radiographic response was assessed following 55 treatments at 3 mo and 30 treatments at 6 months. Response was not assessed for all patients due to both early expiration and lack of radiographic follow-up at our institution since it serves as a tertiary referral center. At 3 mo, 4 patients had a partial response (7.3%), and 27 patients had stable disease (49.1%) with the rest having progressive disease. At 6 mo, 7 patients had a partial response (23.3%), and 10 patients had stable disease (33.3%) with the rest having progressive disease. Median overall survival for all patients was 8.77 mo (95%CI: 6.43-11.11) from the time of first treatment. Thirty-day mortality was 0%.

**DISCUSSION**

Published studies on toxicities associated with 90Y treatment have generally focused on their incidence. While some have focused on univariate analysis of factors predictive of increased toxicity rates, multivariate analysis to account for interaction between these variables remains sparse. We performed this retrospective analysis to further characterize predictors of toxicity to aid in appropriate patient selection and management. Although the majority of treatments resulted in at least one toxicity, severe (grade ≥ 3) toxicities occurred after 21.5% of our treatments (see Table 2).

Although patients had PES following only 12.8% of treatments, many others had symptoms consistent with this syndrome but not ascribed to it. This observation may help explain why some studies report PES in few patients while others report PES in most[8,9]. Incidences of post-treatment ascites, jaundice, and hepatic encephalopathy in our patients was consistent with other studies[19–26]. Incidence of constitutional and GI symptoms in the literature is variable, especially for fatigue[7,19,20,24,25,27], fever[7,11,24,25,27,28], abdominal pain[7,11,19–21,23–25,27,28], and nausea[7,19,20,22,24,25,27,28]. This variability likely proceeds from their subjectivity, different thresholds for categorization, and variable diligence in seeking and documenting evidence of these toxicities. Table 3 compares the incidence of severe toxicities among our patients with that available in the literature, showing that our observed incidence was representative of the literature except for severe albumin toxicity.

In order to assess factors which may predict development of severe toxicities, we performed a multivariate analysis for each severe toxicity. However, since records for clinical toxicities generally did not indicate severity, only LFT toxicities were included. However, we did find that each category of severe toxicity was associated with the development of at least one clinical toxicity (see Supplementary Table 3), suggesting the development of severe laboratory toxicities is clinically relevant. Besides analyzing each severe LFT toxicity individually, we also analyzed the presence of any severe LFT toxicity as this represents underlying post-treatment liver injury regardless of mode. Despite our inability to analyze severe clinical toxicities, each category of severe LFT toxicity was associated with the development of at least 1 clinical toxicity (see Supplementary Table 3), indicating that these laboratory toxicities are clinically relevant. We also did not include radiation-induced liver disease (RILD) as an endpoint as patients were not clinically assessed for the development of certain aspects of RILD. Furthermore, as ascites is a necessary component of RILD and only 1 of our patients had ascites, RILD was not present in enough patients to analyze. Finally, this patient was already included in the analysis of severe hepatic toxicities due to the development of Grade 3 albumin toxicity. We included the MELD score, as calculated using the UNOS modified formula[29], among our variables as an indicator of overall pre-treatment liver function despite it not being validated among this patient population as this is a widely utilized metric of liver function.

Results of our multivariate analyses revealed that pre-treatment laboratory values were important predictors for the presence of post-treatment liver injury. Goin *et al*[23] previously found pre-treatment total bilirubin and increased liver doses to be associated with liver toxicities. Another study[30] found increased pre-treatment bilirubin and AST were both associated with the development of RILD on univariate analysis. Others have provided further support that increased liver dose was associated with liver toxicities[13,31] and RILD[26]. Our binary logistic regression analysis found only pre-treatment albumin levels < 3.4 gm/dL (OR = 26.2; *P =* 0.010) or pre-treatment INR levels > 1.2 (OR = 17.7; *P =* 0.048) predicted development of any severe LFT toxicity. Although increased pre-treatment AST and total bilirubin were significant on univariate analysis, neither were significant on multivariate analysis, and multicollinearity excluded AST, demonstrating the need to assess factors significant on univariate analysis with multivariate analysis. As our patients were treated using the body surface area method without post-treatment SPECT imaging, accurate liver doses could not be determined and could not be included in our analysis.

We further analyzed specific LFTs, including INR and albumin, markers of severe dysfunction of the liver’s biosynthetic capacity[32–34]. Although incidence of post-treatment INR toxicities was only 1.4% and could not be analyzed further, multivariate analysis of severe albumin toxicity showed that pre-treatment AST level > 40 units/L (OR = 7.4; *P =* 0.025) or pre-treatment hemoglobin level < 11.2 gm/dL in women and < 13.4 gm/dL in men (OR = 12.5; *P =* 0.025) were predictors. Another study found liver decompensation, including INR toxicity, to be associated with pre-treatment Child-Pugh Class B[31]. Interestingly, no treatment in patients with Class B had severe albumin toxicity in our study, though this may be due to the low incidence of such patients in our cohort.

We did not analyze markers of severe direct hepatocellular injury, AST and ALT[35], due to their low incidence; however, analysis of severe ALP toxicity, a marker of cholestasis leading to liver injury[36] showed colorectal adenocarcinoma histology to be associated with severe ALP toxicity (OR = 5.4; *P =* 0.043). Of the 14 treatments with severe ALP toxicity, 11 occurred in patients with colorectal adenocarcinoma (78.6%), while none of the 23 treatments in patients with neuroendocrine tumors or cholangiocarcinoma led to severe ALP toxicity.

Multivariate analysis on severe total bilirubin toxicity, a marker of the liver’s ability to transport ions[37], revealed that increasing pre-treatment MELD was associated with increased risk of toxicity (OR = 1.8; *P =* 0.033). Prior studies had found total bilirubin toxicities could be predicted by both cirrhosis[38] and Child-Pugh Class B[31]. Since underlying cirrhosis was an exclusion criterion, we are unable to comment on its predictive ability. Child-Pugh class was not included in multivariate analysis as it had a *P =* 0.462 on univariate.

Some may theorize that sequential bilobar treatments could complicate measurement of toxicities like cirrhosis despite treatments being to different lobes, but incidences of toxicities among our patients were independent of whether patients received treatment to a single lobe or to both (see Supplementary Table 2), and our analysis of severe toxicities revealed each category of severe toxicity was independent of treatment type. We also found that radiographic response did not influence the development of severe toxicities in any examined category (see Supplementary Table 1), indicating our results were not dependent on tumor progression. However, even if incidence of toxicities was overestimated due to inability to differentiate between progression and toxicity, this overestimation is also shared by other studies.

As with any retrospective study, a primary limitation is unintentional bias. The retrospective nature of our analysis prevented grading of clinical toxicities not graded on initial follow-up. The heterogeneity of our patient population reflects that of patients treated with 90Y and reported elsewhere. Since our institution serves as a referral center, some patients were lost to follow-up, while incomplete follow-up was available for others, potentially biasing our results. Though clinicians may have had different thresholds for recording toxicities, no obvious differences were ascertained. While the small sample size of our patients prevented us from performing more extensive analysis of reported toxicities and prevented some factors from being included in multivariate analysis, we were able to perform substantive multivariate toxicity analysis. Further analysis should be performed in a larger cohort of patients both to validate our results and to determine the predictive value of those factors not included in our multivariate analysis. However, even with these limitations, our study achieved its primary objectives.

In conclusion, our multivariate analysis found that patients with decreased pre-treatment albumin were 26.2 times and elevated pre-treatment INR were 17.7 times more likely to develop severe post-treatment liver toxicity. Patients with decreased pre-treatment hemoglobin were 12.5 times more likely to develop post-treatment dysfunction of the liver’s biosynthetic capacity, while patients with increased AST were 7.4 times more likely. Pre-treatment MELD was associated with the development of total bilirubin toxicity, and colorectal adenocarcinoma was associated with development of indirect liver injury. Our results indicate that clinicians should more carefully assess pre-treatment laboratory values, particularly albumin, INR, AST, and hemoglobin when determining the potential risk of 90Y resin microsphere treatment and counseling patients regarding expected severe toxicities and the resultant quality of life. Clinicians should also have greater reservations when recommending 90Y treatment to patients with colorectal adenocarcinoma and elevated MELD scores due to risk for increased toxicity. As such, our results provide a valuable addition to the currently sparse literature regarding multivariate analyses of predictors of severe toxicity after administration of 90Y microspheres.

**ACKNOWLEDGEMENTS**

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**COMMENTS**

***Background***

Beta-emitting yttrium-90 (90Y) microsphere brachytherapy is an important modality for the treatment of unresectable primary or secondary hepatic malignancies that preferentially delivers tumorcidal radiation to hepatic malignancies while sparing normal liver parenchyma. This therapy is associated with the development of both mild and severe toxicities. While many have performed univariate analyses of factors predictive of increased toxicity rates, multivariate analyses to account for interactions between these variables remain sparse.

R***esearch frontiers***

Current research is seeking to determine which patients will benefit the most from this therapy, including which ones are more likely to develop toxicities.

***Innovations and breakthroughs***

Goin *et al* have previously found pre-treatment total bilirubin and higher liver doses to be associated with liver toxicities. Multiple other studies found higher liver disease to be associated with liver toxicitiesand RILD. Othersfound increased pre-treatment bilirubin and AST to be associated with radiation-induced liver disease on univariate analysis. Another study found liver decompensation, including INR toxicity, and total bilirubin toxicity to be associated with pre-treatment Child-Pugh Class B. A final study found total bilirubin toxicities to be associated with cirrhosis.

***Applications***

Clinicians should more carefully assess pre-treatment laboratory values, particularly albumin, INR, AST, and hemoglobin when determining the potential risk of 90Y resin microsphere treatment and counseling patients regarding expected severe toxicities and the resultant quality of life. Furthermore, clinicians should have greater reservations when recommending 90Y treatment to patients with colorectal adenocarcinoma and elevated MELD scores due to risk for increased toxicity. As such, current results provide a valuable addition to the currently sparse literature regarding multivariate analyses of predictors of severe toxicity after administration of 90Y microspheres. Prospective studies should also be performed to validate the results of this study.

***Terminology***

Yttrium-90 microspheres are a type of beta-emitting brachytherapy. Patients with lung shunts > 10% require dose reductions in order to limit the risk of developing radiation pneumonitis. MELD score was based on the UNOS modified formula to provide an indication of underlying liver disease.

***Peer-review***

This manuscript is a well-designed and well-written study detailing variables associated with the development of severe toxicities.

**REFERENCES**

1 **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]

2 **Rothbarth J**, van de Velde CJ. Treatment of liver metastases of colorectal cancer. *Ann Oncol* 2005; **16 Suppl 2**: ii144-ii149 [PMID: 15958446 DOI: 10.1093/annonc/mdi702]

3 **BIERMAN HR**, BYRON RL, KELLEY KH, GRADY A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. *J Natl Cancer Inst* 1951; **12**: 107-131 [PMID: 14874125]

4 **Vente MA**, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van Het Schip AD, Nijsen JF. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol* 2009; **19**: 951-959 [PMID: 18989675 DOI: 10.1007/s00330-008-1211-7]

5 **Bester L**, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. *J Med Imaging Radiat Oncol* 2014; **58**: 341-352 [PMID: 24589204 DOI: 10.1111/1754-9485.12163]

6 **Murthy R**, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. *J Vasc Interv Radiol* 2007; **18**: 553-61; quiz 562 [PMID: 17446547 DOI: 10.1016/j.jvir.2007.02.002]

7 **Kennedy AS**, Coldwell D, Nutting C, Murthy R, Wertman DE, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. *Int J Radiat Oncol Biol Phys* 2006; **65**: 412-425 [PMID: 16690429 DOI: 10.1016/j.ijrobp.2005.12.051]

8 **Sato K**, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S, Nemcek AA, Vogelzang R, Salem R. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. *Cardiovasc Intervent Radiol* 2006; **29**: 522-529 [PMID: 16729228 DOI: 10.1007/s00270-005-0171-4]

9 **Smits ML**, van den Hoven AF, Rosenbaum CE, Zonnenberg BA, Lam MG, Nijsen JF, Koopman M, van den Bosch MA. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases. *PLoS One* 2013; **8**: e69448 [PMID: 23894481 DOI: 10.1371/journal.pone.0069448]

10 **Hilgard P**, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. *Hepatology* 2010; **52**: 1741-1749 [PMID: 21038413 DOI: 10.1002/hep.23944]

11 **Mancini R**, Carpanese L, Sciuto R, Pizzi G, Golfieri R, Giampalma L, Cappelli A, Galaverni MC, Blotta A, Fiore F, Izzo F, Lastoria S, Mastro A, Di Marzo M, Cagol PP, Gasparini D, Geatti O, Bacchetti S, Pasqual E, Zeuli M, Paoletti G, Garufi C, Cosimelli M. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. *In Vivo* 2006; **20**: 711-714 [PMID: 17203751]

12 SIRTeX (October 2011) SIR-Spheres Microspheres (Yttrium-90 Microspheres) Package Insert. Available from: URL: http: //www.sirtex.com/media/43080/ssl-us-09.pdf ((Accessed June 5, 2014))

13 **Kennedy AS**, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. *Int J Radiat Oncol Biol Phys* 2009; **74**: 1494-1500 [PMID: 19157721 DOI: 10.1016/j.ijrobp.2008.10.005]

14 **Sarfaraz M**, Kennedy AS, Lodge MA, Li XA, Wu X, Yu CX. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. *Med Phys* 2004; **31**: 2449-2453 [PMID: 15487724]

15 **Kennedy AS**, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer J* 2010; **16**: 163-175 [PMID: 20404614 DOI: 10.1097/PPO.0b013e3181d7e8cf]

16 **Salem R**, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A. Research reporting standards for radioembolization of hepatic malignancies. *J Vasc Interv Radiol* 2011; **22**: 265-278 [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029]

17 Common Terminology Criteria for Adverse Events (CTCAE) v4.03 (June 14, 2010). Available from: URL: http: //e*vs*nci.nih.gov/ftp1/CTCAE/CTCAE\_4.03\_2010-06-14\_QuickReference\_8.5x11.pdf (Accessed June 5, 2014)

18 **Eisenhauer EA**, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; **45**: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]

19 **Kennedy AS**, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol* 2008; **31**: 271-279 [PMID: 18525307 DOI: 10.1097/COC.0b013e31815e4557]

20 **Geschwind JF**, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S194-S205 [PMID: 15508085 DOI: 10.1053/j.gastro.2004.09.034]

21 **Carr BI**. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. *Liver Transpl* 2004; **10**: S107-S110 [PMID: 14762849 DOI: 10.1002/lt.20036]

22 **Jakobs TF**, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Reiser MF, Helmberger TK. Radioembolization in patients with hepatic metastases from breast cancer. *J Vasc Interv Radiol* 2008; **19**: 683-690 [PMID: 18440456 DOI: 10.1016/j.jvir.2008.01.009]

23 **Goin JE**, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. *J Vasc Interv Radiol* 2005; **16**: 205-213 [PMID: 15713921 DOI: 10.1097/01.RVI.00001142592.89564.F9]

24 **Cosimelli M**, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer* 2010; **103**: 324-331 [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770]

25 **King J**, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer* 2008; **113**: 921-929 [PMID: 18618495 DOI: 10.1002/cncr.23685]

26 **Sangro B**, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2006; **66**: 792-800 [PMID: 16904840 DOI: 10.1016/j.ijrobp.2006.05.065]

27 **Sangro B**, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology* 2011; **54**: 868-878 [PMID: 21618574 DOI: 10.1002/hep.24451]

28 **Coldwell DM**, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. *Int J Radiat Oncol Biol Phys* 2007; **69**: 800-804 [PMID: 17524567 DOI: 10.1016/j.ijrobp.2007.03.056]

29 **Brown RS**, Kumar KS, Russo MW, Kinkhabwala M, Rudow DL, Harren P, Lobritto S, Emond JC. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. *Liver Transpl* 2002; **8**: 278-284 [PMID: 11910574 DOI: 10.1053/jlts.2002.31340]

30 **Lam MG**, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. *Cardiovasc Intervent Radiol* 2013; **36**: 1320-1328 [PMID: 23354961 DOI: 10.1007/s00270-013-0547-9]

31 **Chiesa C**, Mira M, Maccauro M, Romito R, Spreafico C, Sposito C, Bhoori S, Morosi C, Pellizzari S, Negri A, Civelli E, Lanocita R, Camerini T, Bampo C, Carrara M, Seregni E, Marchianò A, Mazzaferro V, Bombardieri E. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. *Q J Nucl Med Mol Imaging* 2012; **56**: 503-508 [PMID: 23358402]

32 **O'Grady JG**, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989; **97**: 439-445 [PMID: 2490426]

33 **Robert A**, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? *Hepatology* 1996; **24**: 1392-1394 [PMID: 8938167 DOI: 10.1002/hep.510240613]

34 **Rothschild MA**, Oratz M, Zimmon D, Schreiber SS, Weiner I, Van Caneghem A. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. *J Clin Invest* 1969; **48**: 344-350 [PMID: 5765785 DOI: 10.1172/JCI105990]

35 **Musana KA**, Yale SH, Abdulkarim AS. Tests of liver injury. *Clin Med Res* 2004; **2**: 129-131 [PMID: 15931347]

36 **Pratt DS**, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med* 2000; **342**: 1266-1271 [PMID: 10781624 DOI: 10.1056/NEJM200004273421707]

37 **Sane RS**, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Böcher WO, Asselah T, Tweedie D. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. *J Pharmacol Exp Ther* 2014; **351**: 403-412 [PMID: 25204339 DOI: 10.1124/jpet.114.218081]

38 **Kulik LM**, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; **47**: 71-81 [PMID: 18027884 DOI: 10.1002/hep.21980]

39 **Piana PM**, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. *J Vasc Interv Radiol* 2011; **22**: 1373-1379 [PMID: 21764600 DOI: 10.1016/j.jvir.2011.06.006]

40 **Rhee TK**, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, Benson AB, Kennedy AS, Omary RA, Salem R. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg* 2008; **247**: 1029-1035 [PMID: 18520231 DOI: 10.1097/SLA.0b013e3181728a45]

**P-Reviewer:** Arslan N, Fiorentini G, Tarazov PG **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Table 1 Baseline characteristics**

|  |  |
| --- | --- |
| **Characteristics1** | **Values2** |
| Sex |  |  |  |
|  Female | 28 | 48.3 |  |
|  Male | 30 | 51.7 |  |
| Race |  |  |  |
|  White | 44 | 75.9 |  |
|  Black | 14 | 24.1 |  |
| Age at primary diagnosis | 57.64 | ± 10.18 | (32-84) |
|  < 65 | 47 | 81.0 |  |
|  ≥ 65 | 11 | 19.0 |  |
| Primary diagnosis |  |  |  |
|  Colorectal adenocarcinoma | 30 | 51.7 |  |
|  Neuroendocrine | 12 | 20.7 |  |
|  Cholangiocarcinoma | 5 | 8.6 |  |
|  Other Primaries | 11 | 19.0 |  |
| Age at liver diagnosis | 58.45 | ± 10.43 | (32-86) |
|  < 65 | 44 | 75.9 |  |
|  ≥ 65 | 14 | 24.1 |  |
| Liver steatosis | 7 | 12.1 |  |
| Number hepatic lesions |  |  |  |
|  < 10 | 11 | 19.0 |  |
|  ≥ 10 | 47 | 81.0 |  |
| Prior treatment |  |  |  |
|  None | 6 | 10.3 |  |
|  Radiofrequency ablation | 6 | 10.3 |  |
|  Surgery | 11 | 19.0 |  |
|  TACE | 3 | 5.2 |  |
|  EBRT | 2 | 3.4 |  |
|  Chemotherapy | 52 | 89.7 |  |
|  Number chemo regimens | 1.78 | ± 1.38 | (0-7) |

|  |  |
| --- | --- |
| **Characteristics3** | **Values2** |
| Age at treatment | 59.54 | ± 10.99 | (32-86) |
|  Years from primary diagnosis | 2.68 | ± 2.79 | (0.14-12.88) |
|  Years from liver diagnosis | 1.85 | ± 1.80 | (0.12-8.49) |
|  < 65 | 53 | 67.1 |  |
|  ≥ 65 | 26 | 32.9 |  |
| KPS |  |  |  |
|  < 80% | 11 | 13.9 |  |
|  ≥ 80% | 68 | 86.1 |  |
| Child-Pugh |  |  |  |
|  A | 74 | 93.7 |  |
|  B | 5 | 6.3 |  |
| MELD score | 7.61 | ± 1.49 | (6-13) |
| Max primary index tumor size (mm) | 61.03 | ± 41.65 | (9-223) |
| Sum primary index tumors (mm) | 82.18 | ± 49.08 | (9-223) |
| Lobe treated |  |  |  |
|  Right | 55 | 69.6 |  |
|  Left | 24 | 30.4 |  |
| BMI (kg/m2) | 26.50 | ± 4.46 | (18.40-36.65) |
| BSA (m2) | 1.89 | ± 0.24 | (1.46-2.65) |
| Total liver |  |  |  |
|  Volume (mL) | 1927.67 | ± 779.16 | (1002-6243) |
|  Tumor volume (mL) | 336.56 | ± 460.83 | (5.1-3096) |
|  % Tumor | 14.35 | ± 11.90 | (0.27-49.59) |
|  < 25% | 62 | 78.5 |  |
|  ≥ 25% | 17 | 21.5 |  |
| Treated liver |  |  |  |
|  Volume (mL) | 1124.06 | ± 585.45 | (346-3946) |
|  Tumor volume (mL) | 253.73 | ± 435.82 | (3-3096) |
|  % Tumor | 17.26 | ± 16.97 | (0.29-78.46) |
|  < 25% | 58 | 73.4 |  |
|  ≥ 25% | 21 | 26.6 |  |
| Lung shunt (%) | 7.11 | ± 3.62 | (1.3-17.4) |
| Calculated dose (mCi) | 27.50 | ± 9.68 | (8.2-56.8) |
|  Unadjusted4 | 47.61 | ± 9.51 | (22.9-77.7) |
| Administered dose (mCi) | 27.48 | ± 9.91 | (8.2-56.9) |
|  Unadjusted | 47.76 | ± 10.64 | (10.6-77.8) |
| Difference in dose (mCi) | -0.02 | ± 1.71 | (-9.53-3.2) |
|  % Difference | -0.25 | ± 8.31 | (-53.84-10.46) |
| Dose to lung (Gy) | 3.40 | ± 1.77 | (0.55-8.41) |
| Intra-procedural Complications |  |  |  |
|  Stasis | 10 | 12.7 |  |
|  Reflux |  |  |  |

1Characteristics by patient; 2Values presented as n (percentage) or mean ± standard deviation (range); 3Characteristics by treatment; 4Unadjusted indicates dose prior to being adjusted for lobar treatment. TACE: Transcatheter arterial chemoembolization; EBRT: External beam radiation therapy;

KPS: Karnofsky Performance Status; MELD: Model for End-Stage Liver Disease; BMI = Body Mass Index; BSA: Body Surface Area; mCi: Millicurie; Gy: Gray.

**Table 2 Toxicity incidence**

|  |  |  |
| --- | --- | --- |
| **Toxicity** | ***n*1** | **Percent** |
| **Post-embolization syndrome2** | **11/86** | **12.79%** |
| **Constitutional toxicities2** | **48/86** | **55.81%** |
| Fatigue | 41/86 | 47.67% |
| Loss of appetite | 15/86 | 17.44% |
| Weakness | 11/86 | 12.79% |
| Fever | 6/86 | 6.98% |
| Weight loss | 5/86 | 5.81% |
| Flu-like symptoms | 5/86 | 5.81% |
| Malaise | 4/86 | 4.65% |
| Chills | 2/86 | 2.33% |
| **Gastrointestinal toxicities2** | **47/85** | **55.29%** |
| Abdominal pain | 34/85 | 40.00% |
| Nausea | 23/85 | 27.06% |
| Emesis | 10/85 | 11.76% |
| Constipation | 6/85 | 7.06% |
| Diarrhea | 3/85 | 3.53% |
| Abdominal Cramps | 1/85 | 1.18% |
| **Hepatic toxicities2** | **38/86** | **44.19%** |
| Alkaline phosphatase | 27/79 | 34.18% |
| Albumin | 21/79 | 26.58% |
| Total bilirubin | 18/79 | 22.78% |
| Aspartate aminotransferase | 9/79 | 11.39% |
| INR | 3/70 | 4.29% |
| Encephalopathy | 2/86 | 2.33% |
| Jaundice | 2/86 | 2.33% |
| Ascites | 1/86 | 1.16% |

1*n* for this Table was determined based on the number of the original 104 patients included in our study with clinical or laboratory follow-up. There were 86 patients with clinical follow-up but only 79 patients with laboratory follow-up, 9 of whom did not have post-treatment INR values obtained; 2High incidence of toxicity. INR: International normalized ratio.

**Table 3 Severe toxicity incidence**

|  |  |  |  |
| --- | --- | --- | --- |
| **Severe toxicities** | **Our patients** | **Time to toxicity development** | **Literature** |
| ***n*** | **%** | **mean** | **SD** | **range** | **Number of resolved1** |  |
| Any | **17** | **21.5** |  |  |  |  | 7%-38%[7,9,39] |
|  INR | 1 | 1.4 | 25.00 |  |  | 0 | 1.3%-1.8%[20,27] |
|  Albumin | 10 | 12.7 | 97.80 | ± 40.59 | (35-174) |  | 0-2%[9,27,40] |
|  AST | 2 | 2.5 | 98.00 | ± 19.80 | (84-112) | 0 | 0-8%[7,9,20,22,23,27,40] |
|  ALT | 0 | 0 |  |  |  |  |
|  ALP | 14 | 17.7 | 86.46 | ± 58.37 | (3-182) | 5 | 0.5%-20%[7,9,20,23,40] |
|  Total bilirubin | 8 | 10.1 | 80.75 | ± 51.63 | (14-182) | 1 | 0-27%[7,9,20,22,23,27,40] |

1Toxicities were considered irreversible if values remained grade ≥ 3 until last recorded measurement. INR: International normalized ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase.

**Table 4 Multivariate analyses of severe toxicities**

|  |  |  |  |
| --- | --- | --- | --- |
| **Toxicity** | **Factor** | **Univariate** | **Multivariate** |
| ***P* value** | **OR** | ***P* value** | **OR** | **95%CI** |
| Any | Pre-treatment albumin | 0.001 | 33.600 | 0.010 | 26.166 | 2.194-312.072 |
| Pre-treatment INR | 0.016 | 9.231 | 0.048 | 17.743 | 1.027-306.461 |
| Colorectal adenocarcinoma | 0.022 | 4.213 | 0.070 | 4.527 | 0.885-23.155 |
| Pre-treatment ALP | 0.018 | 12.343 | 0.187 | 4.770 | 0.468-48.651 |
| Pre-treatment total bilirubin | 0.031 | 13.071 | 0.327 | 33.100 | 0.030-36243.627 |
| Pre-treatment hemoglobin | 0.047 | 3.467 | 0.449 | 1.881 | 0.366-9.674 |
| MELD score | 0.068 | 1.364 | Excluded1 |
| Pre-treatment AST | 0.032 | 3.552 | Excluded1 |
| Albumin | Pre-treatment hemoglobin | 0.040 | 9.265 | 0.025 | 12.492 | 1.349-114.011 |
| Pre-treatment AST | 0.039 | 5.517 | 0.025 | 7.404 | 1.283-42.714 |
| Pre-treatment total bilirubin | 0.047 | 8.375 | 0.355 | 3.349 | 0.259-43.374 |
| Total bilirubin | MELD score | 0.020 | 1.625 | 0.033 | 1.830 | 1.050-3.187 |
| Pre-treatment albumin | 0.035 | 10.138 | 0.056 | 9.042 | 0.941-86.840 |
| Administered dose | 0.099 | 0.933 | 0.117 | 0.922 | 0.833-1.020 |
| Pre-treatment INR | 0.075 | 5.583 | 0.658 | 1.694 | 0.165-17.429 |
| Pre-treatment total bilirubin | 0.025 | 11.500 | Excluded1 |
| ALP | Colorectal adenocarcinoma | 0.030 | 4.552 | 0.043 | 5.362 | 1.058-27.185 |
| Pre-treatment ALP | 0.037 | 9.237 | 0.070 | 15.615 | 0.803-303.636 |
| Pre-treatment hemoglobin | 0.019 | 6.581 | 0.084 | 4.886 | 0.809-29.519 |
| KPS | 0.067 | 0.953 | 0.150 | 0.947 | 0.879-1.020 |
| Pre-treatment INR | 0.049 | 5.636 | 0.189 | 4.903 | 0.456-52.716 |
| KPS < 80 *vs* KPS ≥ 80 | 0.093 | 3.314 | Excluded1 |
| Pre-treatment AST | 0.050 | 3.519 | Excluded1 |

1Variables marked as Excluded were excluded from multivariate analysis due to interdependence. INR: International normalized ratio; ALP: Alkaline phosphatase; MELD: Model for end-stage liver disease; AST: Aspartate aminotransferase; KPS: Karnofsky performance score.